Loading...
Loading...
In a report published Thursday, JP Morgan analyst Geoff Meacham downgraded
CelgeneCELG from Overweight to Neutral and lowered the price target from $180.00 to $170.00.
Despite the company's solid fundamentals, Meacham noted less upside to shares. The analyst wrote, “The change isn't reflective of a new fundamental concern; indeed, Celgene's growth rate is expected to be robust over the next few years.”
Shares of Celgene closed at $154.30 on Wednesday. The stock is currently trading down 0.73 percent in Thursday's pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in